Parkinson’s drug therapies in the clinical trial pipeline: 2024 update
Each year, members of the Cure Parkinson’s research team collaborate with Parkinson’s research advocates and The Michael J. Fox Foundation to present an overview on the current clinical trials landscape for Parkinson’s. The 2024 report, now published in the Journal of Parkinson’s Disease (JPD), marks...
Learn more
Parkinson’s drug therapies in the clinical trial pipeline: 2023 update
Cure Parkinson’s has collaborated annually with Parkinson’s advocates and the Michael J Fox Foundation to present an update on the clinical trials landscape for Parkinson’s. The 2023 report is now published.
Phase 2 UDCA in Parkinson’s trial results published
Cure Parkinson’s is excited to announce that the results from the ‘UP Study’ – a phase 2 study of the liver drug UDCA in Parkinson’s – will be published in the academic journal Movement Disorders.
Our 2023 research impact report
Our recent research impact report determines and highlights the impact our research funding has had on the Parkinson’s research field.
A biomarker for Parkinson’s?
New research from an international consortium led by the Michael J Fox Foundation has highlighted a potential biological biomarker for Parkinson’s.
A new case for GCase
Low levels of a protein called GCase is associated with an increased risk of developing Parkinson’s. New understandings of the role of GCase could help to further explain other biological processes observed in the condition.